Contineum Therapeutics (Contineum Therapeutics) Current Accrued Expense : $4.23 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Current Accrued Expense?

Contineum Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2024 was $4.23 Mil.

Contineum Therapeutics's quarterly Current Accrued Expense declined from Sep. 2023 ($3.09 Mil) to Dec. 2023 ($2.48 Mil) but then increased from Dec. 2023 ($2.48 Mil) to Mar. 2024 ($4.23 Mil).

Contineum Therapeutics's annual Current Accrued Expense declined from Dec. 2021 ($0.76 Mil) to Dec. 2022 ($0.75 Mil) but then increased from Dec. 2022 ($0.75 Mil) to Dec. 2023 ($2.48 Mil).

Contineum Therapeutics Current Accrued Expense Historical Data

The historical data trend for Contineum Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Current Accrued Expense Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Current Accrued Expense

0.76

0.75

2.48

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial			0.75	-	3.09	2.48	4.23

Contineum Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Contineum Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024